Lv3
268 积分 2023-04-18 加入
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
7天前
已完结
Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases
13天前
已完结
Redefining first-line standards with new partners
16天前
已完结
Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations
26天前
已完结
Cancer burden and control in China: landscape, trends and challenges
1个月前
已完结
The promise of bispecific antibodies: Clinical applications and challenges
1个月前
已完结
Immune-checkpoint inhibitors: long-term implications of toxicity
1个月前
已完结
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
1个月前
已完结
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
1个月前
已完结
PD‐L1 immunohistochemistry: Clones, cutoffs, and controversies
1个月前
已完结
皖公网安备34019202002308
